Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Katja Weisel(Universität Hamburg), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Joris Diels(Janssen (Belgium)), Sundar Jagannath(Mount Sinai Hospital), Tonia Nesheiwat, Satish Valluri(Janssen (United States)), Keqin Qi(Janssen (United States)), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), Sandhya Nair(Janssen (Belgium)), Anil Londhe(Janssen (United States)), Martin Vogel(Janssen (United States)), Amrita Krishnan(City of Hope), Ashraf Garrett, Thomas G. Martin(University of Colorado Boulder), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 23
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k